ES510042A0 - "un procedimiento de preparacion de nuevas carboxamidas heterociclicas". - Google Patents

"un procedimiento de preparacion de nuevas carboxamidas heterociclicas".

Info

Publication number
ES510042A0
ES510042A0 ES510042A ES510042A ES510042A0 ES 510042 A0 ES510042 A0 ES 510042A0 ES 510042 A ES510042 A ES 510042A ES 510042 A ES510042 A ES 510042A ES 510042 A0 ES510042 A0 ES 510042A0
Authority
ES
Spain
Prior art keywords
preparation
carboxamides
procedure
heterociclic
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES510042A
Other languages
English (en)
Spanish (es)
Other versions
ES8400409A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo AB
Original Assignee
Leo AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo AB filed Critical Leo AB
Publication of ES8400409A1 publication Critical patent/ES8400409A1/es
Publication of ES510042A0 publication Critical patent/ES510042A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES510042A 1981-03-03 1982-03-02 "un procedimiento de preparacion de nuevas carboxamidas heterociclicas". Granted ES510042A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8106594 1981-03-03

Publications (2)

Publication Number Publication Date
ES8400409A1 ES8400409A1 (es) 1983-10-16
ES510042A0 true ES510042A0 (es) 1983-10-16

Family

ID=10520089

Family Applications (1)

Application Number Title Priority Date Filing Date
ES510042A Granted ES510042A0 (es) 1981-03-03 1982-03-02 "un procedimiento de preparacion de nuevas carboxamidas heterociclicas".

Country Status (21)

Country Link
US (2) US4547511A (OSRAM)
EP (1) EP0059698B1 (OSRAM)
JP (1) JPS57171975A (OSRAM)
KR (1) KR860001876B1 (OSRAM)
AT (1) ATE15798T1 (OSRAM)
AU (1) AU547849B2 (OSRAM)
CA (1) CA1182455A (OSRAM)
DE (1) DE3266464D1 (OSRAM)
DK (1) DK157859C (OSRAM)
ES (1) ES510042A0 (OSRAM)
FI (1) FI79532C (OSRAM)
GR (1) GR76073B (OSRAM)
HK (1) HK38689A (OSRAM)
HU (1) HU186909B (OSRAM)
IE (1) IE52670B1 (OSRAM)
IL (1) IL65028A (OSRAM)
NO (1) NO163130C (OSRAM)
NZ (1) NZ199888A (OSRAM)
PH (1) PH18520A (OSRAM)
PT (1) PT74512B (OSRAM)
ZA (1) ZA821210B (OSRAM)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3269753A (en) * 1964-08-31 1966-08-30 Data Man Inc Bookkeeping unit
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US4400017A (en) * 1981-03-04 1983-08-23 Pendergrass Russell G Integrated budget and check record book
US4650804A (en) * 1984-03-30 1987-03-17 Fujisawa Pharmaceutical Co., Ltd. Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents
DE3420116A1 (de) * 1984-05-30 1985-12-05 Bayer Ag, 5090 Leverkusen Immunstimulierende mittel
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
SE8902076D0 (sv) * 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
US5310913A (en) * 1989-06-09 1994-05-10 Kabi Pharmacia Aktiebolag Derivatives of quinoline-3-carboxanilide
US5691350A (en) * 1990-02-22 1997-11-25 Kabi Pharmacia Ab Use of linomide for treatment of retrovirus infections specifically HIV infections
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
SE9001111D0 (sv) * 1990-03-27 1990-03-27 Pharmacia Ab Supportive use
US5504092A (en) * 1990-03-27 1996-04-02 Pharmacia Ab Use of Linomide to increase hemopoietic cell precursors
JPH06502845A (ja) * 1990-09-07 1994-03-31 シェリング・コーポレーション 抗ウイルス化合物および抗高血圧化合物
CA2091172C (en) * 1990-09-07 1997-05-20 Adriano Afonso Antiviral compounds and antihypertensive compounds
AU8612491A (en) * 1990-09-07 1992-03-30 Schering Corporation Antiviral compounds
US5219864A (en) * 1991-03-12 1993-06-15 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
SE469368B (sv) * 1991-10-09 1993-06-28 Kabi Pharmacia Ab Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms)
TW222276B (OSRAM) * 1992-01-27 1994-04-11 Fujisawa Pharmaceutical Co
SE9201076L (sv) * 1992-04-06 1993-10-07 Shimon Slavin Användningen av gamla läkemedel för behandling av diabetes
GB9311562D0 (en) * 1993-06-04 1993-07-21 Fujisawa Pharmaceutical Co Heterocyclic derivatives
SE9302490D0 (sv) * 1993-07-26 1993-07-26 Kabi Pharmacia Ab New use of old drugs
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
WO1997035565A1 (en) * 1996-03-27 1997-10-02 Toray Industries, Inc. Ketone derivatives and medicinal use thereof
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
JPH1171351A (ja) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
JP2000044561A (ja) * 1998-07-31 2000-02-15 Kyorin Pharmaceut Co Ltd ピロロキノリン誘導体及びその製造方法
JP2000044560A (ja) * 1998-07-31 2000-02-15 Kyorin Pharmaceut Co Ltd ベンゾキノリジン誘導体及びその製造方法
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
RU2240313C2 (ru) * 1999-10-25 2004-11-20 Эктив Байотек Аб Лекарственные средства для лечения злокачественных опухолей
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
PL199781B1 (pl) 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
WO2001034570A1 (en) * 1999-11-08 2001-05-17 Sankyo Company, Limited Nitrogenous heterocycle derivatives
US6525049B2 (en) 2000-07-05 2003-02-25 Pharmacia & Upjohn Company Pyrroloquinolones as antiviral agents
JP2003012667A (ja) * 2001-06-26 2003-01-15 Rrf Kenkyusho:Kk キノリンカルボキサミド骨格を有する抗菌剤
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
WO2004104000A1 (ja) * 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US7228698B2 (en) * 2005-06-30 2007-06-12 Premark Feg L.L.C. Refrigeration unit
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
NZ592897A (en) * 2005-10-19 2012-12-21 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
US7728130B2 (en) * 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
WO2007124617A1 (fr) * 2006-04-28 2007-11-08 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations
KR20160013273A (ko) 2006-06-12 2016-02-03 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
PT2234485E (pt) 2007-12-20 2014-02-17 Teva Pharma Preparações de laquinimod estáveis
PL2276740T3 (pl) 2008-04-28 2015-01-30 Actavis Group Ptc Ehf Ulepszony sposób wytwarzania pochodnych chinolino-3-karboksyamidowych
UA104005C2 (ru) * 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
CN102227424B (zh) 2008-10-23 2013-08-14 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
WO2010059549A1 (en) * 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
EP2376456A2 (en) * 2008-12-17 2011-10-19 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
RS54707B1 (sr) * 2009-07-30 2016-08-31 Teva Pharmaceutical Industries Ltd. Tretman kronove bolesti lakvinimodom
WO2011019375A1 (en) * 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
MX342001B (es) * 2010-03-03 2016-09-09 Teva Pharmaceutical Ind Ltd * Tratamiento de artritis por lupus usando laquinimod.
EA201290837A1 (ru) * 2010-03-03 2013-05-30 Тева Фармасьютикал Индастриз Лтд. Лечение волчаночного нефрита с применением лаквинимода
WO2011109531A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
EP3056205A1 (en) * 2010-07-09 2016-08-17 Teva Pharmaceutical Industries, Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
EP2627638B1 (en) * 2010-10-14 2017-07-12 Immunahr AB 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
FR2967353B1 (fr) * 2010-11-16 2013-08-16 Centre Nat Rech Scient Derives de quinolinone
FR2967498B1 (fr) * 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
WO2013055907A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AU2013214909A1 (en) 2012-02-03 2014-09-18 Teva Pharmaceutical Industries Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNFa therapy
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
TW201350467A (zh) * 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
KR20150091077A (ko) 2012-11-07 2015-08-07 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드의 아민염
EP2970129A2 (en) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
SG11201608674UA (en) 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
WO2018075598A1 (en) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
GB202006390D0 (en) 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
EP4153576A4 (en) * 2020-05-21 2024-06-19 StemSynergy Therapeutics, Inc. NOTCH INHIBITORS AND THEIR USES
CN111732540B (zh) * 2020-07-20 2020-11-13 湖南速博生物技术有限公司 一种罗喹美克的制备方法
TWI838849B (zh) 2021-09-13 2024-04-11 美商美國禮來大藥廠 Ahr促效劑
AR126963A1 (es) 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr
AU2023373727A1 (en) 2022-10-31 2025-05-15 Eli Lilly And Company Ahr agonists
IL320832A (en) * 2022-11-15 2025-07-01 Lilly Co Eli AHR agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH471784A (de) * 1966-01-26 1969-04-30 Bayer Ag Verfahren zur Herstellung von Carbostyrilderivaten
US3524858A (en) * 1967-05-18 1970-08-18 Warner Lambert Pharmaceutical 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
CH578537A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578536A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578534A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578535A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CA1034124A (en) * 1973-05-11 1978-07-04 Ciba-Geigy Ag Process for the manufacture of new quinolines
US3917609A (en) * 1973-06-27 1975-11-04 Minnesota Mining & Mfg Pyrroloquinoline carboxylic acids and derivatives
FR2281761A1 (fr) * 1974-08-13 1976-03-12 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
FR2482596A1 (fr) * 1980-05-19 1981-11-20 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation

Also Published As

Publication number Publication date
ES8400409A1 (es) 1983-10-16
HU186909B (en) 1985-10-28
AU547849B2 (en) 1985-11-07
JPH049786B2 (OSRAM) 1992-02-21
IL65028A0 (en) 1982-04-30
PH18520A (en) 1985-08-02
DK157859B (da) 1990-02-26
DE3266464D1 (en) 1985-10-31
JPS57171975A (en) 1982-10-22
DK157859C (da) 1990-07-30
ATE15798T1 (de) 1985-10-15
KR860001876B1 (ko) 1986-10-24
HK38689A (en) 1989-05-19
US4547511A (en) 1985-10-15
FI79532B (fi) 1989-09-29
CA1182455A (en) 1985-02-12
NZ199888A (en) 1985-07-31
ZA821210B (en) 1983-01-26
EP0059698A1 (en) 1982-09-08
EP0059698B1 (en) 1985-09-25
KR830009037A (ko) 1983-12-17
PT74512A (en) 1982-04-01
PT74512B (en) 1983-11-08
IE820314L (en) 1982-09-03
AU8107682A (en) 1982-09-09
IE52670B1 (en) 1988-01-20
DK81282A (da) 1982-09-04
NO163130B (no) 1990-01-02
FI79532C (fi) 1990-01-10
US4738971A (en) 1988-04-19
NO163130C (no) 1990-04-11
IL65028A (en) 1986-11-30
FI820728L (fi) 1982-09-04
GR76073B (OSRAM) 1984-08-03
NO820642L (no) 1982-09-06

Similar Documents

Publication Publication Date Title
ES510042A0 (es) "un procedimiento de preparacion de nuevas carboxamidas heterociclicas".
OA06914A (fr) Procédé de préparation d'iminodiacides substitués.
FR2417500A1 (fr) Derives d'amino-acides cycliques dehydrogenes et leur utilisation therapeutique
FR2430411A1 (fr) Phenethanolamines et leur utilisation therapeutique
SE8300912D0 (sv) Kompositioner for behandling av glaukom
NO154492C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme forbindelser.
IT1194748B (it) Composizioni farmaceutiche per il trattamento di osteopatie
ES513138A0 (es) "procedimiento de preparacion de compuestos del tipo arilbencensulfonamida".
DE3261760D1 (en) Pharmaceutical compositions for the treatment of skin
RO83114A (ro) Procedeu pentru prepararea ditiazolil-(2,2')-disulfurilor
SE8300913D0 (sv) Kompositioner for behandling av glaukom
DE3268024D1 (en) 0-alkyl-0-carbamoyl-glycero-phospho-cholines and process for their preparation
FR2417499A1 (fr) Mercaptoacylamino-acides halogenes et leur utilisation therapeutique
GB2105992B (en) Pharmaceutical composition for treatment of cardio-vascular diseases
BE894228A (fr) Composition pharmaceutique pour le traitement de l'atherosclerose
NO158299C (no) Analogifremgangsmaate for fremstilling av 17, 18-dehydro-apovincaminol-l-3', 4', 5'-trimethoxy-benzoat.
NO147232C (no) Fremgangsmaate for aa forbedre den biologiske taalbarhet av polyamidimplanteringsproteser
BE892339A (fr) Agents pour le traitement d'affections cardiaques coronariennes
RO81791A2 (ro) Comprimate pentru tratamentul uremiilor feriprive
RO76072A2 (ro) Compozitie medicamentoasa pentru tratamentul afectiunilor cailor respiratorii superioare
IT1135094B (it) Procedimento per la preparazione dell'l-5-idrossitriptofano
NO147752C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 11(eq)-(2-acyletyl)-2,6-metano-3-benzazociner
NO830614L (no) Fremgangsmaate for behandling av glaukom.
RO82224A2 (ro) Procedeu pentru prepararea pivaloil-beta-alanil-p-aminobenzoatului deetil
RO80161A2 (ro) Procedeu pentru prepararea 5-amino-1h-imidazol-4-carboxamidei